跳至主要内容
临床试验/NCT00029536
NCT00029536已完成3 期

Phase 3 Study of Progesterone vs Placebo Therapy

Beth Israel Deaconess Medical Center28 个研究点 分布在 2 个国家目标入组 294 人开始时间: 2000年10月最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
294
试验地点
28
主要终点
Percent of Women Who Show a Greater Than 50% Decline in Average Daily Seizure Frequency

研究概览

简要总结

The purpose of this investigation was to determine if cyclic adjunctive progesterone supplement is superior to placebo in the treatment of intractable seizures in women with and without catamenial epilepsy.

详细描述

This is a 6-month study. The first 3 months will gather baseline information on seizures, antiepileptic drug levels , menstrual cycles, hormone levels, emotional function, and quality of life. The second 3 months will assess the effects of treatment on these parameters.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
13 Years 至 45 Years(Child, Adult)
性别
Female
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Percent of Women Who Show a Greater Than 50% Decline in Average Daily Seizure Frequency

时间窗: 9 years

Percent of women who show a greater than 50% decline in average daily seizure frequency

次要结局

  • Percentage of Women Who Show a Greater Than 50% Decline in Average Daily Seizure Frequency for Secondary Generalized, Complex Partial and Simple Partial Seizures Considered Separately(9 years)
  • Percent of Women Who Show a >50% Decline in Average Daily Seizure Frequency for the Most Severe Seizure Type.(9 years)
  • Changes in Serum Progesterone Levels in Subjects at Baseline and After Treatment.(9 years)
  • Change in Serum Levels of Antiepileptic Drugs on Progesterone and Placebo for Subjects With Catamenial and Non-catamenial Epilepsy.(9 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Andrew Herzog

Professor of Neurology

Beth Israel Deaconess Medical Center

研究点 (28)

Loading locations...

相似试验